Clinical trial
Efficacy and Safety of Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.
Name
[2020]098
Description
The cohort study aims to evaluate the efficacy and safety of steroids combined with anticoagulant therapy compared to standard anticoagulant therapy in acute/subacute severe cerebral venous thrombosis.
Trial arms
Trial start
2018-01-01
Estimated PCD
2021-12-31
Trial end
2021-12-31
Status
Completed
Treatment
Methylprednisolone
In the steroid therapy group, patients received standard treatment plus steroid therapy. Steroid therapy protocol is as follows: 500 mg methylprednisolone once a day, intravenous drip for 3 days, then reduced to 80 mg once a day, intravenous drip for 5 days, and changed to oral methylprednisolone/prednisone 1 mg per kilogram body weight, gradually tapered off by a dose of 10 mg per week.
Arms:
Steroid therapy group
Size
248
Primary endpoint
modified Rankin score(mRS)
6 months after discharge
Eligibility criteria
Inclusion Criteria:
* Acute (within 7 days after symptom onset) or subacute (8-15 days since symptom onset) severe CVT diagnosed by MRI+MRV, CT+CTV, or DSA.
Exclusion Criteria:
* Patients with malignancies
* Patients with incomplete follow-up data.
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 248, 'type': 'ACTUAL'}}
Updated at
2023-08-15
1 organization
1 product
1 indication
Organization
Xuanwu HospitalProduct
MethylprednisoloneIndication
Cerebral Venous Thrombosis